Pneumococcal Infections Pipeline Gains Momentum with Expanding Vaccine Innovation and Advanced Clinical Programs from Sutro Biopharma, Inventprise, Merck, and GSK | DelveInsight

Pneumococcal infections companies such as Sutro Biopharma, Inventprise, Merck, GlaxoSmithKline, CanSinoBIO, LiteVax BV, Panacea Biotec, Virometix AG, Abera Bioscience AB, and others are actively transforming the pneumococcal infections therapeutic and vaccine landscape through innovative vaccine technologies, expanded serotype coverage strategies, and robust clinical development programs.

DelveInsight's "Pneumococcal Infections Pipeline Insight 2026" report provides comprehensive insights into 18+ companies and 20+ pipeline drugs within the Pneumococcal infections pipeline landscape. The report offers a detailed analysis of pipeline drug profiles, including both clinical and nonclinical stage candidates. It further evaluates therapeutics based on product type, stage of development, route of administration, and molecule type while also highlighting inactive and discontinued pipeline products across the indication.

Explore the complete Pneumococcal Infections pipeline landscape and emerging therapeutic opportunities here: Pneumococcal Infections Pipeline Insight Report - https://www.delveinsight.com/report-store/pneumococcal-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Pneumococcal Infections Pipeline Report
• The Pneumococcal infections pipeline includes over 20 active therapeutic and vaccine candidates across multiple stages of development.
• Expanded-valency pneumococcal conjugate vaccines are emerging as a major focus area to address serotype replacement challenges.
• Innovative vaccine platforms utilizing recombinant proteins and advanced conjugation technologies are reshaping preventive strategies.
• Increasing global burden of antimicrobial resistance is driving demand for next-generation pneumococcal vaccines.
• Several pipeline candidates are targeting both pediatric and adult populations to improve broad-based disease prevention.
• Strategic collaborations, licensing agreements, and acquisitions are accelerating clinical development and commercialization activities.
• Novel immunogenicity enhancement technologies are expected to improve vaccine efficacy against invasive pneumococcal disease.
• Emerging companies are increasingly entering the pneumococcal vaccine space, intensifying competition and innovation.
• Clinical trial activity remains robust across Phase I, II, and III studies globally.
• Advances in molecular diagnostics and surveillance systems are supporting more targeted vaccine development approaches.
• In March 2026- Merck Sharp & Dohme LLC initiated a study is to evaluate the safety, tolerability, and immunogenicity of V116 compared to PPSV23 in children and teenagers 2 through 17 years of age, who had completed routine pneumococcal vaccine as infants/toddlers. Researchers want to learn if V116 is as good as, or is better than the PPSV23 vaccine in terms of the antibody immune response. V116 and PPSV23 will be studied in children and teenagers who have a higher risk of getting pneumococcal disease (PD).
• In March 2026- Pfizer conducted a phase 2 study is to learn about the safety, tolerability and immune effects of a pneumococcal vaccine in toddlers. Participants will take part in this study for approximately 6 or 8 months depending on which group they are assigned to. During this time participants will have 2 clinic visits and 1 phone visit for the 1-Dose group, or 3 clinic visits and 1 phone visit for the 2-Dose group.
• DelveInsight's Pneumococcal infections pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Pneumococcal infections treatment.
• The leading Pneumococcal infections Companies such as GlaxoSmithKline, Gangagen, CanSino Biologics Inc., Pfizer, Merck Sharp & Dohme, EuBiologics, Beijing Zhifei Lvzhu Biopharmaceutical, SK Chemicals Co., Ltd., LG Life Sciences, Astellas Pharma, Affinivax, ImmunoBiology, Panacea Biotech, SutroVax, Vaxcyte and others.
• Promising Pneumococcal infections Pipeline Therapies such as V116, PCV15, PPSV23, Sinovac PCV24, V110, V114, Polysaccharide, PPSV23 and others.
• In July 2025, SK bioscience announced that the company and its co-development partner, Sanofi, had received regulatory approval to initiate clinical trials in a pediatric population in China of its 21-valent pneumococcal conjugate vaccine (PCV) candidate, GBP410. This approval marks a key step toward entering one of the world's most strategically important vaccine markets.
• In February 2025, Vaxcyte, Inc. announced that the first study participants have been dosed in the second and final stage of the ongoing Phase II study of VAX-31 in healthy infants. Advancement to Stage II follows a blinded assessment of the Stage 1 safety and tolerability data per the study protocol. This study is evaluating the safety, tolerability and immunogenicity of VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in healthy infants.
• In December 2024, Sanofi and SK bioscience entered into a new chapter of their collaboration in pneumococcal vaccines with an expanded agreement to develop, license and commercialize next-generation PCVs for both pediatric and adult populations, reaffirming their commitment to fighting pneumococcal disease. Under the terms of the expanded agreement, both companies will co-fund research and development costs.
• In November 2024, Vaxcyte, Inc. announced positive regulatory updates, including the United States Food and Drug Administration (FDA) clearance of the VAX-31 infant Investigational New Drug (IND) application and the FDA granting Breakthrough Therapy designation (BTD) for VAX-31 for the prevention of invasive pneumococcal disease (IPD) in adults.
• In October 2024, BioVersys AG, announced the completion of the last patient's last visit in the Phase II clinical trial with its lead asset BV100, the company's novel formulation of rifabutin suitable for intravenous administration. The Phase II multicenter, open label, randomized, active controlled study evaluated the pharmacokinetics, efficacy and safety of BV100 in adult patients with ventilator associated bacterial pneumonia (VABP) suspected or confirmed to be due to Carbapenem Resistant Acinetobacter baumannii (CRAB).
• In September 2024, Vaxcyte, Inc. announced positive topline results from its Phase I/II study of VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate. The study, which involved 1,015 adults aged 50 and older, found that VAX-31 was well tolerated and elicited strong opsonophagocytic activity (OPA) immune responses for all 31 serotypes evaluated.
• In January 2024, Inventprise Inc. announced the completion of vaccination in their Phase II dose ranging study of its 25-valent pneumococcal conjugate vaccine (IVT PCV-25) in young adults. The study is being conducted in four sites in Canada. This vaccine is designed to help prevent pneumococcal disease caused by serotypes not covered in the current PCVs and to help provide protection to people globally, including in low- and middle-income regions where the pneumococcal disease burden is greatest.

Gain strategic intelligence on competitive benchmarking, pipeline dynamics, and clinical advancements in pneumococcal infections: Access Detailed Pneumococcal Infections Pipeline Analytics - https://www.delveinsight.com/sample-request/pneumococcal-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Understanding Pneumococcal Infections: A Persistent Global Health Challenge
Pneumococcal infections, caused by the bacterium Streptococcus pneumoniae, continue to represent a major public health burden worldwide despite significant advancements in vaccination and antimicrobial therapies. The disease disproportionately affects vulnerable populations, including infants, elderly individuals, and immunocompromised patients, contributing substantially to global morbidity and mortality.

Streptococcus pneumoniae commonly colonizes the human nasopharynx and spreads primarily through respiratory droplets. While asymptomatic carriage is common, invasive disease may occur when the pathogen spreads beyond the respiratory tract, leading to severe conditions such as community-acquired pneumonia, meningitis, bacteremia, and sepsis. Noninvasive manifestations, including otitis media and sinusitis, also remain highly prevalent and impose considerable healthcare costs globally.

The growing challenge of pneumococcal disease is closely linked to the emergence of non-vaccine serotypes, antimicrobial resistance, aging populations, and increasing prevalence of chronic diseases that predispose individuals to infection. Although pneumococcal conjugate vaccines have significantly reduced disease incidence and improved herd immunity, evolving serotype distribution continues to necessitate the development of broader-spectrum vaccines and next-generation preventive approaches.
Clinical manifestations of pneumococcal infections vary depending on the site and severity of infection.

Pneumococcal pneumonia often presents with fever, productive cough, chest pain, chills, and breathing difficulty, whereas meningitis may lead to neurological symptoms such as headache, neck stiffness, vomiting, altered consciousness, and seizures. Invasive bloodstream infections may progress rapidly into septic shock and multi-organ dysfunction, particularly among high-risk patients.

Diagnosis relies on clinical evaluation combined with microbiological confirmation of Streptococcus pneumoniae from blood, cerebrospinal fluid, sputum, or other sterile sites. Advanced diagnostic technologies such as polymerase chain reaction (PCR), loop-mediated isothermal amplification (LAMP), urinary antigen detection assays, and MALDI-TOF mass spectrometry are increasingly improving diagnostic accuracy and reducing time to treatment initiation.

Current treatment strategies are centered around prompt antibiotic therapy and supportive care. Mild infections are commonly treated with amoxicillin, doxycycline, or macrolides, while severe infections may require intravenous β-lactams combined with macrolides or fluoroquinolones. The increasing prevalence of antibiotic-resistant strains has intensified the need for innovative preventive vaccines and novel therapeutic approaches capable of addressing resistant pneumococcal serotypes.

Evolving Pneumococcal Infections Pipeline Landscape: Innovation Accelerating Vaccine Development
The Pneumococcal infections pipeline is undergoing rapid transformation, fueled by advancements in conjugate vaccine engineering, recombinant protein technologies, immunogenicity enhancement platforms, and precision antigen targeting strategies. Pharmaceutical and biotechnology companies are actively pursuing expanded-valency vaccines designed to improve serotype coverage and strengthen immune responses across diverse patient populations.

The current pipeline demonstrates strong industry commitment toward reducing invasive pneumococcal disease burden globally. Emerging therapies are increasingly focused on overcoming limitations associated with existing vaccines, particularly serotype replacement and reduced efficacy against evolving pneumococcal strains.

Request comprehensive insights into emerging pneumococcal infection therapies, vaccine innovations, and competitive intelligence: Download the Pneumococcal Infections Pipeline Report Sample - https://www.delveinsight.com/sample-request/pneumococcal-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

According to DelveInsight's analysis, approximately 18+ companies are actively engaged in developing therapies and vaccines for pneumococcal infections, collectively advancing more than 20 pipeline candidates across discovery, preclinical, Phase I, Phase II, and Phase III development stages. The competitive landscape highlights growing emphasis on broad-spectrum conjugate vaccines capable of targeting emerging serotypes while maintaining improved safety and immunogenicity profiles.

The pipeline also reflects increasing collaborations between biotechnology firms, academic institutions, and global vaccine manufacturers aimed at accelerating innovation and commercialization timelines. Strategic licensing agreements, acquisitions, and co-development partnerships are becoming increasingly common as companies seek to strengthen their pneumococcal vaccine portfolios.

Pneumococcal Infections Emerging Drugs Profile
VAX-24: Sutro Biopharma, Inc.
VAX-24 is a next-generation 24-valent pneumococcal conjugate vaccine being developed by Vaxcyte, Inc. for the prevention of invasive pneumococcal infections caused by Streptococcus pneumoniae. The vaccine leverages an advanced cell-free protein synthesis platform designed to enable precise and consistent conjugation of pneumococcal polysaccharide serotypes.

The vaccine aims to provide broader serotype coverage and enhanced immunogenicity compared with currently available pneumococcal vaccines. By targeting 24 serotypes associated with significant global disease burden, VAX-24 seeks to improve protection across pediatric and adult populations while addressing the ongoing challenge of serotype replacement.

Clinical studies have demonstrated promising immunogenicity and safety profiles, positioning the vaccine as a potentially significant advancement within the pneumococcal prevention landscape. VAX-24 is currently undergoing Phase III clinical development and remains among the most advanced pipeline candidates in the indication.

IVT PCV-25: Inventprise
IVT PCV-25 is a 25-valent pneumococcal conjugate vaccine under development by Inventprise, Inc. The vaccine is designed to target 25 pneumococcal serotypes using proprietary conjugation technologies intended to improve immune responses and broaden disease protection.
The candidate is being evaluated for both pediatric and adult populations and is expected to offer expanded serotype coverage beyond several currently marketed vaccines. By incorporating additional serotypes associated with invasive pneumococcal disease, IVT PCV-25 aims to reduce disease incidence across diverse geographic regions.
The vaccine is currently progressing through Phase II clinical trials and reflects the broader industry trend toward expanded-valency conjugate vaccine innovation.

PCV LITE: LiteVax BV
PCV LITE is an investigational pneumococcal conjugate vaccine being developed to provide comprehensive protection against multiple pneumococcal serotypes while potentially improving manufacturing efficiency and affordability. The vaccine utilizes proprietary conjugation approaches intended to maintain strong immunogenicity with optimized antigen composition.
The program highlights increasing efforts to improve vaccine accessibility and scalability for global immunization initiatives, particularly in low- and middle-income countries where pneumococcal disease burden remains high.

V118C: Merck
V118C is an investigational pneumococcal vaccine candidate being developed by Merck to expand protection against invasive pneumococcal disease. The candidate reflects Merck's continued commitment to strengthening its vaccine portfolio through broader serotype inclusion and advanced immunogenicity strategies.
The program is designed to support preventive care across multiple patient populations and contribute to global disease reduction initiatives.

GSK5459248: GlaxoSmithKline
GSK5459248 is part of GlaxoSmithKline's growing infectious disease vaccine pipeline focused on addressing pneumococcal infections through next-generation conjugate vaccine technologies. The candidate aims to enhance immune responses and improve protection against evolving pneumococcal serotypes.
The development program underscores increasing industry focus on long-term disease prevention through broader and more durable immunization strategies.

Pneumococcal Infections Pipeline Segmentation and Therapeutic Assessment
The report provides detailed segmentation and therapeutic assessment of Pneumococcal infections pipeline products based on development stage, route of administration, molecule type, and product classification.
Pneumococcal Infections Clinical Trial Phases
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I)
• Preclinical and discovery-stage candidates
• Inactive and discontinued programs

Pneumococcal Infections Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Pneumococcal Infections Molecule Types
• Recombinant fusion proteins
• Small molecules
• Monoclonal antibodies
• Peptides
• Polymers
• Gene therapies

Pneumococcal Infections Product Types
• Mono therapies
• Combination therapies
• Mono/Combination approaches
These varied therapeutic approaches demonstrate the complexity of pneumococcal disease management and the growing need for innovative preventive and therapeutic solutions capable of addressing evolving pathogen dynamics.

Pneumococcal Infections Clinical Trial and Development Activities
Clinical trial activity within the Pneumococcal infections space continues to accelerate as companies intensify efforts to address unmet medical needs and strengthen competitive positioning. Multiple vaccine candidates are progressing through global clinical trials evaluating immunogenicity, safety, serotype coverage, and long-term efficacy across diverse patient populations.

Companies are increasingly adopting strategic partnerships, licensing agreements, and collaborative research initiatives to accelerate product development timelines and improve commercialization potential. Academic institutions and biotechnology companies are also playing an important role in advancing novel vaccine technologies and antigen discovery programs.

The growing emphasis on expanded-valency conjugate vaccines reflects a broader industry objective of improving protection against emerging serotypes while minimizing the risk of serotype replacement. In parallel, advancements in recombinant technologies and precision conjugation methods are contributing to improved vaccine consistency and enhanced immune response generation.

Explore detailed clinical trial intelligence, partnership activities, and emerging pneumococcal vaccine innovations: View Comprehensive Pneumococcal Infections Clinical Trial Insights - - https://www.delveinsight.com/sample-request/pneumococcal-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Pneumococcal Infections Market Drivers, Challenges, and Future Outlook
Several factors are expected to drive significant growth within the Pneumococcal infections pipeline market over the coming years. Increasing prevalence of respiratory infections, rising antimicrobial resistance, expanding elderly populations, and growing awareness regarding adult immunization programs are among the major contributors supporting market expansion.

Global immunization initiatives and public health programs are also encouraging broader vaccine adoption, particularly in regions with high disease burden. In addition, technological advancements in vaccine engineering and molecular diagnostics are facilitating the development of more targeted and effective preventive strategies.

However, challenges such as evolving serotype epidemiology, high vaccine development costs, complex regulatory pathways, and disparities in vaccine accessibility continue to impact market dynamics. Addressing these barriers will require continued investment in research and development, global surveillance systems, and healthcare infrastructure improvements.

Despite these challenges, the future outlook for the Pneumococcal infections pipeline remains highly promising. Several late-stage vaccine candidates are expected to advance toward regulatory submission and commercialization in the coming years, potentially reshaping global pneumococcal disease prevention strategies.
The integration of advanced immunology research, artificial intelligence-driven vaccine design, and next-generation conjugation platforms is likely to accelerate innovation further and redefine the future landscape of pneumococcal infection prevention and management.

Stay informed about the latest Pneumococcal infections pipeline developments, emerging therapies, and strategic opportunities with DelveInsight's comprehensive market intelligence report:
Get Full Pneumococcal Infections Pipeline Intelligence Report - https://www.delveinsight.com/sample-request/pneumococcal-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Pneumococcal Infections Pipeline Report
• Coverage: Global
• Key Companies: Sutro Biopharma, Inventprise, LiteVax BV, Merck, GlaxoSmithKline, CanSinoBIO, Abera Bioscience AB, GPN Vaccines, Panacea Biotec, Virometix AG, and others
• Key Products: VAX-24, IVT PCV-25, PCV LITE, V118C, GSK5459248, PCV24, Ab-01.12, Gamma-PN, NuVac-23, V-212
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment by Clinical Stage: Discovery, Preclinical, Phase I, Phase II, Phase III

Table of Contents
1. Introduction
2. Executive Summary
3. Pneumococcal Infections Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Analytical Perspective
7. Late-Stage Products
8. Mid-Stage Products
9. Early-Stage Products
10. Inactive Products
11. Key Companies
12. Key Products
13. Unmet Needs
14. Market Drivers and Barriers
15. Future Perspectives

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.